Engineered DNA molecule for coding RNA

MYPI2025005318A0Undetermined Publication Date: 2024-09-01RINUAGENE BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025005318
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-23
Filing Date
2024-02-29
Publication Date
2024-09-01

AI Technical Summary

Technical Problem

In the existing technology, the Poly(A) tail is unstable during the replication process in E. coli, causing the in vivo stability and biological activity of the mRNA to be affected, making it difficult to achieve large-scale production.

Method used

An engineered DNA molecule containing a polyadenine tail was designed. Its coding sequence is composed of specific elements to ensure the conservation of the Poly(A) tail during in vitro preparation and regulate the RNA expression through specific structure and sequence combinations. Expression levels in eukaryotic cells.

Benefits of technology

It improves the stability of the Poly(A) tail during in vitro preparation and its expression regulation ability in eukaryotic cells, ensuring the stability and biological activity of mRNA, and is suitable for large-scale production and functional regulation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025005318_DRAWING_001
    Figure PI2025005318_DRAWING_001
  • Figure PI2025005318_DRAWING_002
    Figure PI2025005318_DRAWING_002
  • Figure PI2025005318_DRAWING_003
    Figure PI2025005318_DRAWING_003
Patent Text Reader

Abstract

An engineered DNA molecule capable of being replicated in a cell, comprising a poly (A) tail coding sequence that makes the engineered DNA molecule more conservative when replicated in cells, particularly in prokaryotic cells, while adjusting the expression level of RNA in eukaryotic cells. Also provided are an RNA comprising the poly (A) tail and a use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Engineered DNA molecules encoding RNA Technical Field

[0001] The present application relates to the field of biotechnology, and more particularly to an RNA comprising a poly(A) tail. The poly(A) tail allows the replication of the DNA encoding the RNA to be more stable in prokaryotic systems and can be used to regulate the expression level of the RNA in eukaryotic cells. Background Art

[0002] The primary structure of a translatable mRNA therapeutic molecule consists of a 5' cap, a 5' untranslated region (5'UTR), a coding region, a 3' untranslated region, and a polyadenylic acid tail (poly(A) tail). The poly(A) tail is known to maintain mRNA stability in vivo and participate in the initiation of protein translation, the latter of which is achieved through the interaction of poly(A) tail binding protein (PABP) with the translation initiation complex. In eukaryotic cells, the poly(A) tail is synthesized as a post-transcriptional modification by a typical poly(A) polymerase.

[0003] The first step in preparing mRNA drugs in vitro is to synthesize them through in vitro transcription (IVT) using a linearized plasmid containing the designed product sequence as a template. The poly(A) tail is usually added co-transcriptionally downstream of the 3'UTR. To achieve co-transcriptional addition of poly(A), the corresponding poly(dA:dT) sequence needs to be included in the template plasmid. However, the poly(dA:dT) repeat sequence in the plasmid is unstable during replication in Escherichia coli, and deletion mutations often occur, resulting in shortening of the poly(dA:dT). This phenomenon is not conducive to the preparation process of in vitro transcription template plasmids for large-scale production through fermentation, and poly(A) truncation has a significant impact on the in vivo stability and biological activity of mRNA.

[0004] SUMMARY OF THE INVENTION

[0005] This application provides a novel Poly(A) tail to enhance its conservation during in vitro preparation and a method for regulating RNA expression levels in eukaryotic cells based on the Poly(A) tail.

[0006] Specifically, the first aspect of the present application provides an engineered DNA molecule that can replicate in a cell, comprising a polyadenosine tail (Poly (A) tail) coding sequence, wherein the Poly (A) tail coding sequence comprises:

[0007] a sole element a and at least one element b, and at least one element c;

[0008] a sole element a and at least one element b, and at least one element d; or

[0009] a sole element a and at least one element b, as well as at least one element c and at least one element d,

[0010] In the poly (A) tail coding sequence, the element a is composed of a plurality of consecutive adenine (A) nucleotides, and the length of the element a ranges from ≥20 nt;

[0011] The element b consists of a plurality of consecutive A nucleotides, and the length of the element b ranges from 3nt≤b<20nt;

[0012] The element c consists of a non-A nucleotide, and the nucleotide is selected from T, C, and G nucleotides;

[0013] The element d is composed of any two or more consecutive nucleotides selected from A, T, C, and G nucleotides, wherein the nucleotides at the 5' and 3' ends of the element d are not A nucleotides, and the element d does not contain more than three consecutive A nucleotides; the length of the element d is in the range of 2nt≤d≤20nt;

[0014] wherein element a and element b are not adjacent, and element c and element d are not adjacent,

[0015] Furthermore, the Poly(A) tail coding sequence does not contain adjacent elements b, does not contain adjacent elements c, and does not contain adjacent elements d.

[0016] In some embodiments, the Poly (A) tail coding sequence further comprises a single element e, which consists of one or two consecutive A's; and is located at the 3' end of the Poly (A) tail coding sequence and adjacent to element d or element c.

[0017] In some embodiments, the Poly(A) tail encoding sequence does not contain elements other than element a, element b, element c, and element d.

[0018] In some embodiments, the Poly(A) tail encoding sequence does not contain any elements other than element a, element b, element c, element d, and element e.

[0019] In some embodiments, the poly (A) tail coding sequence comprises at least two elements d. In some embodiments, the poly (A) tail coding sequence comprises at least two elements c. In some embodiments, the poly (A) tail coding sequence comprises at least one element d and one element c.

[0020] In some embodiments, the number of the elements b is 2-10, for example, 3, 4, 5, 6, 7, 8, or 9.

[0021] In some embodiments, the number of the elements c is 0 to 10, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9.

[0022] In some embodiments, the number of the elements d is 0 to 5, such as 1, 2, 3, or 4.

[0023] In some embodiments, when element c and element d are present at the same time, the total number of elements c and d is 2-15, for example, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14.

[0024] In some embodiments, the number of the element a is 1, the number of the element b is 3, the number of the element c is 2, and the number of the element d is 1.

[0025] In some embodiments, the number of the element a is 1, the number of the element b is 4, the number of the element c is 4, and the number of the element d is 1.

[0026] In some embodiments, the number of the element a is 1, the number of the element b is 5, the number of the element c is 4, and the number of the element d is 1.

[0027] In some embodiments, the number of the element a is 1, the number of the element b is 3, the number of the element c is 3, and the number of the element d is 1.

[0028] In some embodiments, the number of the element a is 1, the number of the element b is 3, the number of the element c is 2, and the number of the element d is 1.

[0029] In some embodiments, the element a is ≤ 80 nt. In some embodiments, the element a is 21nt, 22nt, 23nt, 24nt, 25nt, 26nt, 27nt, 28nt, 29nt, 30nt, 31nt, 32nt, 33nt, 34nt, 35nt, 36nt, 37nt, 38nt, 39nt, 40nt, 41nt, 42nt, 43nt, 44nt, 45nt, 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt, 55nt, 56nt, 57nt, 58nt, 59nt, 60nt, 61nt, 62nt, 63nt, 64nt, 65nt, 66nt, 67nt, 68nt, 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, or 79nt.

[0030] In some embodiments, the element b is 3nt, 4nt, 5nt, 6nt, 7nt, 8nt, 9nt, 10nt, 11nt, 12nt, 13nt, 14nt, 15nt, 16nt, 17nt, 18nt, or 19nt.

[0031] In some embodiments, the element d is 2nt≤d≤20nt, 3 to 18nt, 5 to 16nt, 4 to 10nt, or 6 to 12nt, for example, 2nt, 3nt, 4nt, 5nt, 6nt, 7nt, 8nt, 9nt, 10nt, 11nt, 12nt, 13nt, 14nt, 15nt, 16nt, 17nt, 18nt, 19nt or 20nt, preferably 6nt.

[0032] In some embodiments, the length of the poly (A) tail coding sequence is greater than 40nt, for example, 41nt, 42nt, 43nt, 44nt, 45nt, 46nt, 47nt, 48nt, 49nt, 50nt, 51nt, 52nt, 53nt, 54nt, 55nt, 56nt, 57nt, 58nt, 59nt, 60nt, 61nt, 62nt, 63nt, 64nt, 65nt, 66nt, 67nt, 68nt, 69nt, 70nt, 71nt, 72nt, 73nt, 74nt, 75nt, 76nt, 77nt, 78nt, 79nt, 80nt ,81nt,82nt,83nt,84nt,85nt,86nt,87nt,88nt,89nt,90nt,91nt,92nt,93nt,94nt,95nt,96nt,97nt,98nt,99nt,100nt,101nt,102nt,103 nt, 104nt, 105nt, 106nt, 107nt, 108nt, 109nt, 110nt, 111nt, 112nt, 113nt, 114nt, 115nt, 116nt, 117nt, 118nt, 119nt, 120nt, 121nt, 122nt, 123nt, 124nt, 125nt, 126nt, 127nt, 128nt, 129nt, 130nt, 131nt, 132nt, 133nt, 134nt, 135nt, 136nt, 137nt, 138nt, 139nt, 140nt, 141nt, 142nt, 143nt, 144nt, 145nt, 146nt, 147nt, 148nt, 149nt, 150nt, 151nt, 152nt, 153nt, 154nt, 155nt, 156nt, 157nt, 158nt, 159nt, 160nt, 161nt, 162nt, 163nt, 164nt, 165nt, 166nt, 167nt, 168nt, 169nt, 170nt, 171nt, 172nt, 173nt, 174nt, 175nt, 176nt, 177nt, 178nt, 179nt, 180nt, 181nt, 182nt, 183nt, 184nt, 185nt, 186nt, 187nt, 188nt, 189nt, 190nt, 191nt, 192nt, 193nt, 194nt, 195nt, 196nt, 197nt, 198nt, 199nt, 200nt, 201nt, 202nt, 203nt, 204nt, 205nt, 206nt, 207nt, 208nt, 209nt, 210nt,<h2 style=";text-align:left;direction:ltr">211nt, 212nt, 213nt, 214nt, 215nt, 216nt, 217nt, 218nt, 219nt, 220nt, 221nt, 222nt, 223nt, 224nt, 225nt, 226nt, 227nt, 228nt, 229nt, 230nt, 231n t、232nt、233nt、234nt、235nt、236nt、237nt、238nt、239nt、240nt、241nt、 242nt、243nt、244nt、245nt、246nt、247nt、248nt、249nt、250nt、251nt、252nt nt、253nt、254nt、255nt、256nt、257nt、258nt、259nt、260nt、261nt、262nt 、263nt、264nt、265nt、266nt、267nt、268nt、269nt、270nt、271nt、272nt、2 73nt, 274nt, 275nt, 276nt, 277nt, 278nt, 279nt, 280nt, 281nt, 282nt, 283nt, 284nt, 285nt, 286nt, 287nt, 288nt, 289nt, 290nt, 291nt, 292nt, 293nt 294nt, 295nt, 296nt, 297nt, 298nt, 299nt, 300nt, 301nt, 302nt, 303nt, 304nt, 305nt, 306nt, 307nt, 308nt, 309nt, 310nt, 311nt, 312nt, 313nt, 314n t、315nt、316nt、317nt、318nt、319nt、320nt、321nt、322nt、323nt、324nt、 325nt、326nt、327nt、328nt、329nt、330nt、331nt、332nt、333nt、334nt、335nt nt、336nt、337nt、338nt、339nt、340nt、341nt、342nt、343nt、344nt、345nt 、346nt、347nt、348nt、349nt、350nt、351nt、352nt、353nt、354nt、355nt、3 56nt, 357nt, 358nt, 359nt, 360nt, 361nt, 362nt, 363nt, 364nt, 365nt, 366nt, 367nt, 368nt, 369nt, 370nt, 371nt, 372nt, 373nt, 374nt, 375nt, 376nt377nt, 378nt, 379nt, 380nt, 381nt, 382nt, 383nt, 384nt, 385nt, 386nt, 387nt, 388nt, 389nt, 390nt, 391nt, 392nt, 393nt, 394nt, 395nt, 396nt, 397nt, 398nt, 399nt, 400nt, etc.

[0033] In some embodiments, 50% or more of the polynucleotides of element a are located in the 5' portion or 3' portion of the poly(A) tail coding sequence. In some embodiments, more than 50% of the polynucleotides of element a are located in the 5' portion of the poly(A) tail coding sequence. In some embodiments, more than 50% of the polynucleotides of element a are located in the 3' portion of the poly(A) tail coding sequence. In some embodiments, the number of nucleotides of element a located in the 3' portion of the poly(A) tail coding sequence is equal to the number of nucleotides located in the 5' portion of the poly(A) tail coding sequence.

[0034] In some embodiments, the element c is G, C, or T.

[0035] In some embodiments, the element d comprises a palindrome sequence. Element d is a palindrome sequence. In some embodiments, the element d comprises a sequence selected from the group consisting of GATATC (SEQ ID NO: 15), GTATAC (SEQ ID NO: 16), GAATCT (SEQ ID NO: 17), GCATATGACT (SEQ ID NO: 18), and GATATCGTATAC (SEQ ID NO: 19). In some embodiments, the element d is a sequence selected from the group consisting of GATATC (SEQ ID NO: 15), GTATAC (SEQ ID NO: 16), GAATCT (SEQ ID NO: 17), GCATATGACT (SEQ ID NO: 18), and GATATCGTATAC (SEQ ID NO: 19). In some embodiments, the element d comprises the polynucleotide sequence shown in SEQ ID NO: 15. In some embodiments, the polynucleotide sequence of the element d is shown in SEQ ID NO: 15.

[0036] In some embodiments, the nucleotide at the 3' end of the poly(A) tail encoding sequence is A. In some embodiments, the nucleotide at the 3' end of the poly(A) tail encoding sequence is G. In some embodiments, the nucleotide at the 3' end of the poly(A) tail encoding sequence is C. In some embodiments, the nucleotide at the 3' end of the poly(A) tail encoding sequence is T.

[0037] In some embodiments, the 3' portion of the poly (A) tail coding sequence comprises one or more non-A nucleotides. In some embodiments, the poly (A) tail coding sequence comprises one or more non-A nucleotides in the 1 / 2 portion near the 3' end. In some embodiments, the poly (A) tail coding sequence comprises one or more non-A nucleotides in the 1 / 3 portion near the 3' end. In some embodiments, the poly (A) tail coding sequence comprises one or more non-A nucleotides in the 1 / 4 portion near the 3' end.

[0038] In some embodiments, the structure of the Poly(A) tail encoding sequence is:

[0039] Element a-element c-element b-element c-element b-element c-element b-element c-element b;

[0040] Element b-element c-element b-element c-element a-element d-element b-element c-element b-element c-element b;

[0041] Element b-element c-element b-element c-element b-element d-element a-element c;

[0042] element a-element d-element b-element c-element b-element c-element b; or

[0043] Element b-element c-element b-element c-element b-element d-element a.

[0044] In some embodiments, the structure of the Poly(A) tail encoding sequence is:

[0045] Element a-element c-element b-element c-element b-element c-element b-element c-element b; specifically 60A-G-19A-G-19A-G-19A-G-3A.

[0046] In some embodiments, the structure of the Poly(A) tail encoding sequence is:

[0047] 7A-C-18A-G-60A-GG-7A-C-18A-G-14A,

[0048] 19A-G-19A-G-19A-component d-60A-G,

[0049] 60A-component d-19A-G-19A-G-17A,

[0050] 19A-G-19A-G-19A-component d-60A,

[0051] 19A-G-19A-G-19A-component d-60A,

[0052] 19A-C-19A-C-19A-element d-60A,

[0053] 19A-T-19A-T-19A-component d-60A,

[0054] 19A-G-19A-G-19A-element d-60A, or

[0055] 19A-G-19A-G-19A-element d-60A;

[0056] And wherein element d consists of 6 or 12 nucleotides.

[0057] In some embodiments, the Poly(A) tail encoding sequence is as shown in any one of SEQ ID NOs: 1 to 10.

[0058] In some embodiments, the Poly(A) tail encoding sequence is shown as SEQ ID NO: 3 or SEQ ID NO: 4.

[0059] In some embodiments, the engineered DNA molecule is further linked to a target gene fragment at the 5' end of its poly(A) tail coding sequence, and the target gene fragment and the poly(A) tail coding sequence together encode RNA. In some embodiments, the engineered DNA molecule is further linked to a target gene fragment at the 5' end of its poly(A) tail coding sequence, and the target gene fragment and the poly(A) tail coding sequence together encode mRNA. In some embodiments, the target gene fragment comprises a protein-coding sequence or a non-protein-coding sequence, such as a functional RNA-coding sequence. In some embodiments, the target gene fragment further comprises a 5'UTR coding sequence at the 5' end of the protein-coding sequence or the functional RNA-coding sequence. In some embodiments, the target gene fragment further comprises a 3'UTR coding sequence at the 3' end of the protein-coding sequence or the functional RNA-coding sequence. In some embodiments, the target gene fragment further comprises a 3'UTR coding sequence at the 3' end of the protein-coding sequence or the functional RNA-coding sequence, and further comprises a 5'UTR coding sequence at the 5' end of the protein-coding sequence or the functional RNA-coding sequence. In some embodiments, the engineered DNA molecule further comprises a replicon, such as an origin of replication, such as an ORI. In some embodiments, the engineered DNA molecule further comprises a marker gene to facilitate screening of cells containing the engineered DNA molecule, and the marker gene is selected from, for example, antibiotic resistance genes, fluorescent proteins, etc. In some embodiments, the DNA molecule further comprises a promoter, which initiates transcription of the RNA co-encoded by the target gene fragment and the poly (A) tail coding sequence. In some embodiments, the promoter is a prokaryotic promoter. In some embodiments, the promoter is a eukaryotic promoter. In some embodiments, the DNA molecule further comprises a replicon, such as an origin of replication, a promoter, a 5'UTR coding sequence, a protein coding sequence, and a 3'UTR coding sequence. In some embodiments, the DNA molecule further comprises a replicon, such as an origin of replication, a resistance gene, a 5'UTR coding sequence, a protein coding sequence, and a 3'UTR coding sequence. In some embodiments, the DNA molecule further comprises a replicon, such as a replication origin, a resistance gene, a promoter, a 5'UTR coding sequence, a protein coding sequence, and a 3'UTR coding sequence. In some embodiments, the protein coding sequence encodes an HPV viral antigen protein. In some embodiments, the HPV protein is derived from HPV type 16 and / or type 18. In some embodiments, the protein coding sequence encodes the HPV E2, E6, or E7 protein. In some embodiments, the protein coding sequence encodes a fusion protein of the HPV E6 and E7 proteins.In some embodiments, the protein coding sequence encodes a fusion protein of HPV E2, E6, and E7 proteins. In some embodiments, the polypeptide fragment of the fusion protein is derived from HPV types 16 and / or 18. In some embodiments, the polypeptide fragment of the fusion protein is derived from HPV types 16 and / or 18 E2, E6, and E7 proteins. In some embodiments, the protein coding sequence encodes the polypeptide set forth in SEQ NO: 26 or a conservatively substituted variant thereof.

[0060] In some embodiments, the engineered DNA molecule comprises a polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25, or a synonymous mutant of the polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25, or a polynucleotide sequence having greater than 85% sequence identity with the polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25 or a synonymous mutant thereof.

[0061] In some embodiments, the DNA molecule is a DNA plasmid. In some embodiments, the DNA molecule is a linear plasmid or a circular plasmid. In some embodiments, the DNA molecule is single-stranded or double-stranded. In some embodiments, the plasmid is a plasmid based on pUC, pTZ, pMB1, or pCoIE1. In some embodiments, the plasmid is a plasmid based on the pUC57 vector.

[0062] In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a recA-bacterium. In some embodiments, the cell is Escherichia coli. In some embodiments, the Escherichia coli is selected from the group consisting of K-12 and its derivatives, and B strain and its derivatives. In some embodiments, the Escherichia coli is selected from the group consisting of MG1655, DH5 or DH5α, DH10B, BL21, DB3.1, HB101, JM109, JM110, MC1061, MG1655, Pir, Stbl2, Stbl3, Top10, XL1Blue, XL10Gold, BLR, HMS174, Tuner, Rostetta2, Lemo21, T7Express, and Origami2.

[0063] The second aspect of the present application discloses a cell comprising the DNA molecule of the aforementioned first aspect. In some embodiments, the DNA molecule of the aforementioned first aspect can be replicated and / or transcribed in the cell. In some embodiments, the cell is a prokaryotic cell, and the DNA molecule of the aforementioned first aspect can be replicated in the prokaryotic cell. In some embodiments, the cell is a recA-bacterium. In some embodiments, the cell is Escherichia coli. In some embodiments, the prokaryotic cell is a competent cell. In some embodiments, the prokaryotic cell is an engineered cell. In some embodiments, the prokaryotic cell is an engineered prokaryotic cell. In some embodiments, the cell is Escherichia coli, and the Escherichia coli is selected from: K-12 and its derivatives, and B strain and its derivatives. In some embodiments, the Escherichia coli is selected from the group consisting of: MG1655, DH5 or DH5α, DH10B, BL21, DB3.1, HB101, JM109, JM110, MC1061, MG1655, Pir1, Stbl2, Stbl3, Top10, XL1Blue, XL10Gold, BLR, HMS174, Tuner, Rostetta2, Lemo21, T7Express, Origami2. In some embodiments, the cell is a eukaryotic cell, and the DNA molecule of the first aspect can be transcribed in the eukaryotic cell. In some embodiments, the eukaryotic cell is a mammalian cell. In some embodiments, the eukaryotic cell is selected from a yeast or a mold.

[0064] The third aspect of the present application provides a Poly(A) tail. The Poly(A) tail:

[0065] (1) obtained by transcription of the engineered DNA molecule of the first aspect;

[0066] (2) obtained by chemical synthesis and having the same polynucleotide sequence as the poly(A) tail obtained by transcription of the engineered DNA molecule of the first aspect; or

[0067] (3) The poly (A) tail in (1) or (2) is further modified to obtain the poly (A) tail.

[0068] In some embodiments, the further modification comprises replacing one or more ribonucleotides in the poly (A) tail obtained by (1) or (2) with one or more deoxyribonucleotides. In some embodiments, the one or more ribonucleotides are replaced with deoxyribonucleotides corresponding to the one or more ribonucleotides, for example, one or more ribonucleotides A in the poly (A) tail are replaced with deoxyribonucleotides A, one or more ribonucleotides U are replaced with deoxyribonucleotides T, one or more ribonucleotides C are replaced with deoxyribonucleotides C, one or more ribonucleotides G are replaced with deoxyribonucleotides G, or one or more ribonucleotides G are replaced with ribonucleotides I (inosine) or deoxyribonucleotides I. In some embodiments, the modification is a chemical modification. In some embodiments, the modification is a base editing. In some embodiments, the modification deaminates one or more ribonucleotides in the poly (A) tail obtained by (1) or (2).

[0069] In some embodiments, the poly(A) tail comprises a polynucleotide sequence selected from any one of SEQ ID NOs: 1-10. In some embodiments, the polynucleotide sequence of the poly(A) tail is as shown in any one of SEQ ID NOs: 1-10.

[0070] The present application also provides the use of the aforementioned Poly (A) tail. In some embodiments, the Poly (A) tail is used to make an RNA molecule more stable, wherein the Poly (A) tail is located at the 3' end of the RNA, and the more stable is more stable outside the cell, inside the cell, or in the animal body relative to the RNA molecule containing another Poly (A) tail. In some embodiments, the Poly (A) tail is used to reduce the stability of an RNA molecule, wherein the Poly (A) tail is located at the 3' end of the RNA, and the reduction in stability is a reduction in stability outside the cell, inside the cell, or in the animal body relative to the RNA molecule containing another Poly (A) tail. In some embodiments, the Poly (A) tail is used to increase the expression level of an RNA molecule in the same period of time, and the increased expression level is an increased expression level outside the cell, inside the cell, or in the animal body relative to the RNA molecule containing another Poly (A) tail. In some embodiments, the Poly (A) tail is used to reduce the expression level of an RNA molecule in the same period of time, and the increased expression level is relative to the reduced expression level of an RNA molecule comprising another Poly (A) tail, outside the cell, inside the cell, or in the animal body. In some embodiments, the Poly (A) tail is used to extend the expression time of an RNA molecule, and the extended expression time is relative to the extended expression time of an RNA molecule comprising another Poly (A) tail, outside the cell, inside the cell, or in the animal body. In some embodiments, the Poly (A) tail is used to shorten the expression time of an RNA molecule, and the extended expression time is relative to the shortened expression time of an RNA molecule comprising another Poly (A) tail, outside the cell, inside the cell, or in the animal body. In some embodiments, the Poly (A) tail is used to extend the half-life of an RNA molecule, and the extended half-life is relative to the extended half-life of an RNA molecule comprising another Poly (A) tail, outside the cell, inside the cell, or in the animal body. In some embodiments, the poly (A) tail is used to shorten the half-life of an RNA molecule, wherein the shortened half-life is shortened outside a cell, inside a cell, or in an animal relative to an RNA molecule comprising another poly (A) tail.

[0071] In some embodiments, the RNA molecule is an mRNA molecule. In some embodiments, the poly (A) tail and the other poly (A) tail are two different poly (A) tails belonging to the poly (A) tail of the third aspect of the present application. In some embodiments, the poly (A) tail is a poly (A) tail belonging to the third aspect of the present application, and the other poly (A) tail is a poly (A) tail other than the poly (A) tail of the third aspect of the present application. In some embodiments, the intracellular is a host cell, and the host cell is a eukaryotic cell. In some embodiments, the host cell is a mammalian cell. In some embodiments, the host cell is a human cell.

[0072] The present application also provides a DNA fragment or a hybrid molecule fragment of DNA and RNA encoding the poly (A) tail of the third aspect of the present application, and the use of the DNA fragment or the hybrid molecule fragment of DNA and RNA to make the replication of the DNA molecule encoding RNA or the hybrid molecule of DNA and RNA more conservative in the host cell, wherein the DNA fragment or the hybrid molecule fragment of DNA and RNA encoding the poly (A) tail of the third aspect of the present application is located on the 3' end of the RNA coding sequence in the DNA molecule or the hybrid molecule of DNA and RNA. In some embodiments, the host cell is a prokaryotic cell. In some embodiments, the host cell is a recA-bacterium. In some embodiments, the host cell is Escherichia coli. In some embodiments, the Escherichia coli is selected from: K-12 and its derivatives, and B strain and its derivatives. In some embodiments, the E. coli is selected from: MG1655, DH5 or DH5α, DH10B, BL21, DB3.1, HB101, JM109, JM110, MC1061, MG1655, Pir, Stbl2, Stbl3, Top10, XL1Blue, XL10Gold, BLR, HMS174, Tuner, Rostetta2, Lemo21, T7Express, Origami2.

[0073] The fourth aspect of the present application further provides an RNA molecule, wherein the RNA molecule comprises the Poly(A) tail of the third aspect. In some embodiments, the RNA molecule is an mRNA molecule. In some embodiments, the RNA molecule:

[0074] (1) obtained by transcription of the engineered DNA molecule of the first aspect;

[0075] (2) obtained by chemical synthesis and having the same polynucleotide sequence as the RNA molecule of item (1); or

[0076] (3) Obtained by further modifying the RNA molecule in the aforementioned (1) or (2).

[0077] In some embodiments, the further modification comprises replacing one or more ribonucleotides in the RNA molecule obtained by (1) or (2) with one or more deoxyribonucleotides. In some embodiments, the one or more ribonucleotides are replaced with deoxyribonucleotides corresponding to the one or more ribonucleotides, for example, one or more ribonucleotides A of the RNA molecule are replaced with deoxyribonucleotides A, one or more ribonucleotides U are replaced with deoxyribonucleotides T, one or more ribonucleotides C are replaced with deoxyribonucleotides C, one or more ribonucleotides G are replaced with deoxyribonucleotides G, or one or more ribonucleotides G are replaced with ribonucleotides I (inosine) or deoxyribonucleotides I. In some embodiments, the modification is a chemical modification. In some embodiments, the modification is a base editing. In some embodiments, the modification is a deamination treatment of one or more ribonucleotides in the RNA molecule obtained by (1) or (2). In some embodiments, the further modification is a post-transcriptional modification. In some embodiments, the further modification comprises capping. In some embodiments, the further modification comprises splicing. In some embodiments, the further modification comprises splicing and capping.

[0078] In some embodiments, the RNA molecule comprises coding RNA or non-coding RNA (ncRNA). In some embodiments, the RNA molecule is pre-mRNA. In some embodiments, the RNA is mature mRNA. In some embodiments, the RNA molecule is long noncoding RNA (lncRNA). In some embodiments, the RNA molecule further comprises a 5'-cap structure. In some embodiments, the polynucleotide sequence of the RNA molecule is as shown in any one of SEQ ID NOs: 22-25. In some embodiments, the RNA molecule comprises a polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25.

[0079] In addition, the present application also provides a hybrid molecule of DNA and RNA, which carries the same genetic information as the engineered DNA molecule of the first aspect, the same genetic information as the Poly (A) tail of the third aspect, or the same genetic information as the RNA molecule of the fourth aspect.

[0080] In addition, the present application also provides a nucleic acid molecule library. In some embodiments, the nucleic acid molecule library comprises the engineered DNA molecule of the first aspect, the Poly(A) tail of the third aspect, a DNA fragment or a hybrid molecule fragment of DNA and RNA encoding the Poly(A) tail of the third aspect of the present application, or the RNA molecule of the fourth aspect.

[0081] In addition, the present application also provides a method for regulating protein expression, comprising: introducing multiple nucleic acid molecules from the aforementioned nucleic acid molecule library into a target cell at different times and / or in different quantitative ratios. In some embodiments, the nucleic acid molecule is the engineered DNA molecule of the aforementioned first aspect. In some embodiments, the nucleic acid molecule is the RNA molecule of the aforementioned fourth aspect.

[0082] It should be understood that the aspects and embodiments of the present application described herein include aspects and embodiments that "comprise," "consist of," and "consist essentially of." The preferred embodiments of the present application are described in detail above, but the present application is not limited thereto. Within the technical concept of the present application, various simple variations of the technical solution of the present application may be made, including combining the various technical features in any other suitable manner. These simple variations and combinations should also be considered as disclosed in the present application and fall within the scope of protection of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] FIG1 shows the replication stability of 10 poly(A) proteins in the present application in Escherichia coli DH5α in Example 2;

[0084] FIG2 shows the base deletion statistics of the 10 poly(A)s in this application in E. coli DH5α in Example 2;

[0085] Figure 3 shows the replication stability of poly(A) P1, P2, P3, P4 and poly(A) controls C1 and C2 in Example 3 in Escherichia coli DH5α in a plasmid system containing HPV antigen sequences;

[0086] FIG4 shows the base deletion statistics of poly(A) P3, P4 and poly(A) controls C1 and C2 in Example 3 in E. coli DH5α in a plasmid system including HPV antigen sequences;

[0087] FIG5 shows a comparison of the replication stability of poly(A) P1, P2, P3 and poly(A) control C1 in Example 3 at 30° C. and 37° C. in E. coli DH5α in a plasmid system containing HPV antigen sequences;

[0088] FIG6 shows an example of a map of a universal vector plasmid DNA in the Examples.

[0089] FIG7 shows the animal imaging results of the expression levels of luciferase in mice with poly(A) P3, P4, P5, P8, P9 and the control C2 in Example 4;

[0090] FIG8 shows the quantitative results of fluorescence intensity after animal imaging of the expression levels of luciferase with poly(A) P3, P4, P5, P8, P9 and control C2 in mice in Example 4 (ns, no significant difference; ★★ , significant difference, p<0.01).

[0091] Detailed Description of the Invention

[0092] The present application first provides a method for stably amplifying a poly(A) tail transcription template DNA in vitro to reduce the mutation frequency of the poly(A) tail transcription template sequence when the DNA is replicated in large quantities in cells. Thus, a large number of RNAs containing a poly(A) tail with a defined sequence are obtained based on the DNA. On this basis, RNAs, such as mRNAs, engineered to have a specific function with a poly(A) tail can be produced on a large scale through in vitro fermentation.

[0093] In addition, the present application also provides a DNA containing a poly (A) tail transcription template that can be stably amplified in vitro, and RNA transcribed from the DNA. Further, under the premise of satisfying in vitro stable amplification, the present application further provides a group of poly (A) tails that have different regulatory effects on RNA stability and / or expression efficiency, RNA containing the poly (A) tail, DNA containing the poly (A) tail encoding sequence, and a library consisting of the poly (A) tail, the RNA or the DNA.

[0094] Furthermore, the present application also provides uses of the aforementioned Poly(A) tail, RNA, DNA, and library.

[0095] the term

[0096] As used herein, "element a," "element b," "element c," "element d," and "element e" are categories of elements that may be included in Poly(A). Element a is composed of a plurality of consecutive adenine (A) nucleotides, and the length of element a is ≥20 nt; element b is composed of a plurality of consecutive A nucleotides, and the length of element b is 3nt≤b<20 nt; element c is composed of one non-A nucleotide, and the nucleotide is selected from T, C, and G nucleotides; element d is composed of any two or more consecutive nucleotides, and the nucleotides are selected from A, T, C, and G nucleotides, wherein the nucleotides at the 5' and 3' ends of element d are not A nucleotides, and element d does not contain more than three consecutive A nucleotides, and the length of element d is 2nt≤d≤20nt. Element e is composed of one or two consecutive A nucleotides, and when present, it is located at the 3' end of the Poly(A) tail coding sequence and adjacent to element d or element c. When a Poly(A) contains two or more "element b," "element c," and "element d," the sequences of every two element b may be the same or different, the sequences of every two element c may be the same or different, and the sequences of every two element d may be the same or different, as long as they each meet the aforementioned definitions of element a, b, c, and d. In this application, "element a," "element b," "element c," "element d," "element e," etc. at the end of Poly(A) may all be referred to by the term "element."

[0097] As used herein, when describing the positional relationship of two or more elements as "non-adjacent," it means that the two or more elements are not adjacent to each other. In other words, the two or more elements contain at least one or more other nucleotides or bases other than the nucleotides of the two elements.

[0098] In this article, "coding" refers to i) the genetic information contained in the DNA sequence that can be transcribed into an RNA molecule, and / or ii) the genetic information contained in the RNA molecule that can be translated into an amino acid sequence. Therefore, as used herein, "coding sequence" can be used to refer to a ribonucleotide (RNA) sequence or a fragment thereof in an mRNA precursor or mature mRNA that can be translated into a protein, and can also refer to the complementary sequence of a deoxyribonucleotide (DNA) sequence or a fragment thereof that is used as a template for transcribing the mRNA precursor or mature mRNA. In addition, the "coding sequence" of the present application can further include polynucleotide sequences that encode proteins, functional nucleic acids, or fragments thereof, such as miRNA, shRNA, dsRNA, guide RNA, Poly (A) tail, 5'UTR, 3'UTR, etc. Among them, a DNA molecule containing genetic information that can be transcribed into an RNA molecule is called the "coding nucleic acid" of the RNA molecule; an RNA molecule containing genetic information that can be translated into an amino acid sequence is called the "coding nucleic acid" of the amino acid sequence.

[0099] In this application, the nucleotides in all polynucleotide sequences are numbered from the 5' end to the 3' end, that is, the nucleotide at the 5' end is the first nucleotide, and the nucleotide at the 3' end is the last nucleotide. Unless otherwise specified, "5' end" and "5' end" can be used interchangeably; "3' end" and "3' end" can be used interchangeably. "5' end" and "3' end" focus on describing the relative positional relationship between nucleotides, between nucleotide sequence segments, or between nucleotides and nucleotide sequence segments in the same nucleic acid sequence; "5' end" and "3' end" are used to describe the positions of the first and last nucleotides of a nucleic acid sequence or a segment of a nucleic acid sequence, respectively. "5' end side" is used to describe the relative positional relationship between two sequences with no overlapping parts in the same polynucleotide sequence. When describing a sequence as being located on the 5' end side of another sequence, it means that the sequence is closer to the "5' end" of the polynucleotide sequence relative to the other sequence. Similarly, when describing a sequence as being located on the 3' end of another sequence, it means that one sequence is closer to the "3' end" of the polynucleotide sequence relative to the other sequence, and the one sequence and the other sequence do not contain any overlapping parts. For example, "the DNA coding sequence of the Poly (A) tail is located at the 3' end of the RNA coding sequence" means that the DNA coding sequence of the Poly (A) tail is a component of the RNA coding sequence and contains the nucleotides at the 3' end of the RNA coding sequence. In addition, as used herein, "5' part" refers to the half of the polynucleotide sequence that is close to the 5' end of the polynucleotide sequence, with the "center position" of the polynucleotide sequence as the boundary. "3' part" refers to the half of the polynucleotide sequence that is close to the 3' end of the polynucleotide sequence, with the center position of the polynucleotide sequence as the boundary. The number of nucleotides from the "center position" to the 5' end and to the 3' end described in this application is equal.

[0100] As used herein, when the term "conservative" is used to describe the replication of a nucleic acid molecule, it means that the probability of mutations occurring during the replication process is low. In this context, "conservative" is a relative concept. For example, when describing "a DNA coding sequence of a poly(A) tail is used to make the replication of a DNA molecule encoding an RNA more conservative in a host cell," it means that after a parent DNA molecule encoding an RNA is replicated into a daughter DNA molecule, if the RNA molecule contains the poly(A) tail, then the probability that the daughter DNA molecule has 100% sequence identity with the parent DNA molecule is higher than that of the DNA coding for the RNA molecule that does not contain the poly(A) tail (e.g., an RNA molecule containing some other poly(A) tail); or the average sequence identity between the multiple daughter DNA molecules obtained by replication of the parent DNA molecule and the parent DNA molecule is higher.

[0101] In this application, when describing the expression of "regulating" an RNA molecule, the "regulating" means: increasing or decreasing the total amount of the protein or functional RNA expressed by the RNA molecule within the same time period; or enabling the RNA to express the protein or functional RNA within a longer or shorter time frame, and the increase, decrease, or longer or shorter time frame is relative to another RNA molecule expressing the same protein or functional RNA. When describing the expression of a protein, it refers to regulating the expression of an RNA molecule containing the protein coding sequence. The regulatory effect described here can be achieved by connecting the Poly (A) tail of the present application to the 3' end of an RNA molecule that does not contain a Poly (A) tail, or by replacing the original Poly (A) tail of the RNA with the Poly (A) tail of the present application.

[0102] As used herein, percentages of "identity," such as 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, or 99.5% identity, refer to a degree of similarity between amino acid sequences or nucleotide sequences determined by sequence alignment of 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99%, or 99.5%. For example, the percentage of positions with identical bases or amino acid residues is determined as a ratio of the total number of positions after two sequences have been aligned to have identical residues at as many positions as possible, such as by introducing gaps. Percentages of "identity" can be determined using software programs known in the art. Preferably, the alignment is performed using default parameters. A preferred alignment program is BLAST. Preferred programs are BLASTN and BLASTP. Details of these programs can be found on the Internet at the following address: ncbi.nlm.nih.gov / cgi-bin / BLAST.

[0103] As used herein, the "complementarity" of nucleic acids refers to the ability of a nucleic acid to form hydrogen bonds with another nucleic acid through traditional Watson-Crick base pairing. Percent complementarity represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (i.e., Watson-Crick base pairing) with another nucleic acid molecule (e.g., about 5, 6, 7, 8, 9, 10 out of 10 are about 50%, 60%, 70%, 80%, 90% and 100% complementary, respectively). "Completely complementary" refers to that all consecutive residues of a nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in a second nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity of at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% over a region of about 40, 50, 60, 70, 80, 100, 150, 200, 250 or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions. For single bases or nucleotides, according to the Watson-Crick base pairing principle, when A pairs with T or U, or C pairs with G or I, they are considered complementary or matching, and vice versa; all other base pairings are considered non-complementary. In this application, the "complementary polynucleotide sequence" of a polynucleotide sequence refers to a polynucleotide sequence that is completely complementary to the polynucleotide sequence.

[0104] As used herein, a "conservative substitution variant" of a protein, polypeptide or amino acid sequence refers to one in which one or more amino acid residues undergo amino acid substitution without changing the overall conformation and function of the protein or enzyme, including but not limited to replacing the amino acids in the amino acid sequence of the parent protein in the manner described by the aforementioned "conservative substitution". Therefore, the similarity of two proteins or amino acid sequences with similar functions may be different. For example, a similarity (identity) of 70% to 99% based on the MEGALIGN algorithm. "Conservative substitution variants" also include polypeptides or enzymes with more than 60% amino acid identity as determined by the BLAST or FASTA algorithm, preferably more than 75%, preferably more than 85%, and even more than 90%, and have the same or substantially similar properties or functions as the natural or parent protein or enzyme.

[0105] In the context of this application, the terms "DNA" and "RNA" refer to single-stranded or double-stranded DNA or RNA molecules. Unless otherwise indicated, the terms "DNA" and "DNA molecule" refer to double-stranded DNA molecules composed of A, C, G and / or T nucleotides, while the terms "RNA" and "RNA molecule" refer to single-stranded RNA molecules composed of A, C, G and / or U nucleotides. In this article, the A, C, G, T and U nucleotides refer to nucleotides containing adenine, guanine, cytosine, thymine and uracil as their respective nitrogenous bases.

[0106] RNA molecules include coding RNA or non-coding RNA (ncRNA), such as pre-mRNA, mature mRNA or long noncoding RNA (lncRNA).

[0107] As used herein, the "DNA and RNA hybrid molecule" is a molecule comprising a polynucleotide sequence consisting of deoxyribonucleotides and ribonucleotides. The DNA and RNA hybrid molecule can be obtained by:

[0108] Replace one or more deoxyribonucleotides in DNA with ribonucleotides;

[0109] Substituting one or more ribonucleotides in the RNA with deoxyribonucleotides; or

[0110] De novo synthesis using deoxyribonucleotides and ribonucleotides as raw materials through biological or chemical synthesis. It should be noted that the methods for obtaining DNA / RNA hybrid molecules are not limited to the above methods; DNA / RNA hybrid molecules obtained by any method fall within the scope of "DNA / RNA hybrid molecules" as defined in this application.

[0111] As used herein, when two nucleic acid molecules are described as having "the same genetic information", it means that the two nucleic acid molecules are complementary, or contain exactly the same base sequence, or that after one or more thymines in the base sequence of one nucleic acid molecule are converted to uracil, a nucleic acid molecule with exactly the same base sequence as the other nucleic acid molecule can be obtained. Therefore, any two of DNA, RNA, and hybrid molecules of DNA and RNA can have the same genetic information. Among them, the term "base sequence" refers to the order in which bases are arranged in a polynucleotide molecule. It should be understood by those skilled in the art that, unless otherwise specified, the base sequence or polynucleotide sequence described in this application can be used to represent thymine when used to describe a DNA sequence, but when the base sequence or polynucleotide sequence is used to describe RNA (e.g., mRNA), "T" will be replaced by "U" (uracil). Therefore, any DNA disclosed by a specific sequence number (SEQ ID NO) herein also discloses an RNA (e.g., mRNA or Poly (A) tail) sequence that is complementary or corresponding to the DNA, wherein each "T" in the DNA sequence is replaced by a "U".

[0112] Poly(A) tail and its use

[0113] As used herein, the term "Poly A tail" or "Poly (A) sequence" refers to an uninterrupted or uninterrupted sequence of adenylate residues typically located at the 3'-end of an RNA molecule. In RNA, the Poly-A sequence is attached to the 3' end of the 3'-UTR, if present. An uninterrupted poly-A tail is characterized by a continuous sequence of adenylate residues. The poly-A tail can be of any length. In some embodiments, the poly-A tail comprises, or consists of, at least 20, at least 30, at least 40, at least 80, or at least 100 and at most 500, at most 400, at most 300, at most 200, or at most 150 adenylate residues (A), particularly about 120 A's. Typically, the vast majority of nucleotides in the PolyA tail are adenosine, where the vast majority refers to at least 75%, at least 80%, at least 85%, at least 90% of the nucleotides, etc., but the remaining nucleotides are allowed to be nucleotides other than A (non-A nucleotides), such as U (uridylic acid), G (guanylic acid) or C (cytidylic acid).

[0114] In some embodiments, the in vitro RNA production process is a prokaryotic fermentation process, i.e., a nucleic acid encoding an RNA molecule containing the poly(A) tail is introduced into prokaryotic cells, the prokaryotic cells are amplified to achieve the purpose of amplifying the encoding nucleic acid, and the amplified encoding nucleic acid is subsequently transcribed into the RNA. In some embodiments, the in vitro RNA production process involves ligating an RNA fragment containing a protein-coding sequence to a poly(A) tail through homologous recombination, enzymatic ligation, or other non-homologous recombination methods, and the poly(A) tail is produced through a prokaryotic fermentation process, during which the encoding nucleic acid containing the poly(A) tail is introduced into prokaryotic cells, the prokaryotic cells are amplified to achieve the purpose of amplifying the encoding nucleic acid, and the amplified encoding nucleic acid is subsequently transcribed into RNA containing the poly(A) tail. In some embodiments, the encoding nucleic acid is linear. In some embodiments, the encoding nucleic acid is circular. In some embodiments, the encoding nucleic acid is a plasmid. In some embodiments, the encoding nucleic acid is single-stranded or double-stranded. In some embodiments, the encoding nucleic acid is chemically modified prior to introduction into prokaryotic cells. In some embodiments, the aforementioned encoding nucleic acid is chemically synthesized before introduction into a prokaryotic cell. In some embodiments, the encoding nucleic acid is inserted into the genomic DNA of the nucleoid / nucleoid of the prokaryotic cell. In some embodiments, the encoding nucleic acid is free in the cytoplasm of the prokaryotic cell or outside the nucleoid / nucleoid. In some embodiments, the prokaryotic cell is Escherichia coli.

[0115] Based on this, the present application provides a series of Poly(A) tails that are highly conserved during the in vitro preparation of RNA. The Poly(A) tails contain one or more non-A nucleotides at one or more positions.

[0116] In some embodiments, the Poly(A) tail encoding sequence comprises:

[0117] a sole element a and at least one element b, and at least one element c;

[0118] a sole element a and at least one element b, and at least one element d; or

[0119] a sole element a and at least one element b, as well as at least one element c and at least one element d,

[0120] wherein element a and element b are not adjacent, and element c and element d are not adjacent,

[0121] Furthermore, the Poly(A) tail coding sequence does not contain adjacent elements b, does not contain adjacent elements c, and does not contain adjacent elements d.

[0122] In some embodiments, the Poly(A) tail coding sequence further comprises a single element e, which consists of one or two consecutive A's and is located at the 3' end of the Poly(A) tail coding sequence and adjacent to element d or element c.

[0123] The Poly(A) tail here can be a segment of RNA or a hybrid molecule of DNA and RNA.

[0124] The present application also provides a Poly(A) tail that can regulate protein expression levels. Furthermore, the present application also provides a Poly(A) tail that can regulate protein expression levels while being highly conserved during in vitro preparation. In some embodiments, the structure of the Poly(A) tail that can regulate protein expression levels; or the structure of the Poly(A) tail that can regulate protein expression levels while being highly conserved during in vitro preparation is selected from:

[0125] Element a-element c-element b-element c-element b-element c-element b-element c-element b;

[0126] Element b-element c-element b-element c-element a-element d-element b-element c-element b-element c-element b;

[0127] Element b-element c-element b-element c-element b-element d-element a-element c;

[0128] element a-element d-element b-element c-element b-element c-element b; and

[0129] Element b-element c-element b-element c-element b-element d-element a.

[0130] In some embodiments, the poly(A) tail capable of regulating protein expression levels; or the poly(A) tail capable of regulating protein expression levels, which is highly conserved during in vitro preparation, is selected from the group consisting of:

[0131] 60A-G-19A-G-19A-G-19A-G-3A;

[0132] 7A-C-18A-G-60A-element d-7A-C-18A-G-14A;

[0133] 60A-element d-19A-G-19A-G-17A;

[0134] 19A-G-19A-G-19A-element d-60A;

[0135] 19A-G-19A-G-19A-element d-60A-G;

[0136] 19A-G-19A-G-19A-element d-60A;

[0137] 19A-C-19A-C-19A-element d-60A; and

[0138] 19A-T-19A-T-19A-element d-60A.

[0139] In some embodiments, the Poly (A) tail that can regulate protein expression levels; or the structure of the Poly (A) tail that can regulate protein expression levels while being highly conserved during the in vitro preparation process is: 60A-element d-19A-G-19A-G-17A or 19A-G-19A-G-19A-element d-60A.

[0140] The two elements connected by "-" are directly connected, and there is no nucleotide between the two elements.

[0141] In the above-mentioned Poly(A) tail structure, "yA" represents the number of consecutive A's in element a or element b, where y is a natural number. For example, 19A means that it contains 19 consecutive A's; 60A means that it contains 60 consecutive A's.

[0142] In some embodiments, the Poly(A) tail capable of regulating protein expression levels; or the polynucleotide coding sequence of the Poly(A) tail capable of regulating protein expression levels that is highly conserved during in vitro preparation is selected from a polynucleotide sequence as shown in any one of SEQ ID NOs: 1-10.

[0143] In addition, the present application also provides the use of the above-mentioned Poly(A) tail for regulating protein expression, in which the Poly(A) tail is located at the 3' end of the mRNA, such as the 3' end of the 3' UTR. In some embodiments, the regulating protein expression uses the method for regulating protein expression described below.

[0144] Engineered DNA molecules and libraries

[0145] The application also provides a kind of engineered DNA molecule that can be replicated in cell, and it comprises the coding sequence of aforementioned Poly A tail or its complementary sequence.Those skilled in the art will appreciate that, except the coding sequence of described Poly A tail, described engineered DNA molecule should also comprise and can make described DNA molecule replicate in cell, or efficient replication necessary structural element.Making described engineered DNA molecule replicate in cell or efficient replication necessary structural element is known in the art, including such as origin of replication (ORI).In some embodiments, described engineered DNA molecule also further comprises marker gene or its fragment and / or reporter gene or its fragment and allows to insert unique restriction endonuclease site of DNA element, preferably restriction endonuclease site of multiple cloning site (MCS) form.Described marker gene is conducive to identifying the cell containing the plasmid comprising described marker gene, can be selected from, such as antibiotic resistance gene.Each restriction endonuclease site in described MCS all can be by different restriction endonuclease specific recognition.

[0146] In some embodiments, the DNA molecule is a DNA plasmid. As used herein, the term "DNA plasmid" refers to a plasmid consisting of a double-stranded DNA molecule. In some embodiments, the "plasmid" is a circular DNA molecule. In some embodiments, the "plasmid" can also encompass linear DNA molecules. Specifically, the term "plasmid" also encompasses molecules obtained by, for example, cutting a circular plasmid with a restriction endonuclease, thereby converting the circular plasmid molecule into a linear molecule and linearizing the circular plasmid, as well as linear molecules that can be replicated in prokaryotes. Plasmids can replicate, i.e., amplify the genomic genetic information stored in the cell independently of the prokaryotic nucleoid or nucleoid, and can be used for cloning, i.e., for amplifying genetic information in bacterial cells. Preferably, the DNA plasmid according to the present application is a medium copy or high copy plasmid, more preferably a high copy plasmid. Examples of such high copy plasmids are vectors based on pUC, pTZ plasmids, or any other plasmids (e.g., pMB1, pCoIE1) containing an ORI that supports high copies of the plasmid.

[0147] In some embodiments, the DNA molecule is a DNA molecule or a fragment thereof constituting a nucleoid or nucleoid of a prokaryotic organism, that is, the coding sequence or its complementary sequence comprising the aforementioned Poly (A) tail can be replicated along with the prokaryotic genome.

[0148] In some embodiments, the DNA molecule is further connected to a target gene fragment on the 5' end side of the poly (A) tail coding sequence, and the target gene fragment and the poly (A) tail coding sequence jointly encode RNA. In some embodiments, the target gene fragment and the poly (A) tail coding sequence jointly encode mRNA. The target gene fragment comprises a coding sequence for a protein, polypeptide or a fragment thereof. In some embodiments, the target gene fragment further comprises a coding sequence for an element that can be used to initiate or regulate the expression of the protein, polypeptide or a fragment thereof after transcription, and the element includes but is not limited to a 5'UTR, a 3'UTR, etc. In some embodiments, the target gene fragment comprises a coding sequence for at least one untranslated region (UTR). In some embodiments, the target gene fragment comprises at least the coding sequence of the 5'UTR and the coding sequence of the protein, polypeptide or a fragment thereof. In some embodiments, the target gene fragment comprises at least the coding sequence of the 5'UTR, the coding sequence of the protein, polypeptide or a fragment thereof, and the coding sequence of the 3'UTR from 5' to 3'. The coding sequence of the protein, polypeptide or fragment thereof can be ultimately translated into one or more proteins, or one or more polypeptides, such as short peptides, oligopeptides, polypeptides, fusion proteins, proteins and fragments thereof, such as portions of known proteins, such as functional portions. The functional portion can be, for example, a biologically active portion of a protein or an antigenic portion that can effectively produce antibodies, such as an antigenic epitope. The two ends of the coding sequence of the protein, polypeptide or fragment thereof respectively contain a start codon (5' end) and a stop codon (3' end), which are the first three nucleotides and the last three nucleotides that can be translated of the mRNA molecule, respectively. The 5'UTR typically contains at least one ribosome binding site (RBS), such as the Shine-Dalgarno sequence in prokaryotes, or at least one translation initiation site, such as the Kozak sequence in eukaryotes. The RBS promotes efficient and accurate translation of the mRNA molecule by recruiting ribosomes at the start of translation. The activity of a given RBS or translation initiation site can be optimized by varying its length and sequence, as well as its distance from the start codon. Optionally or optionally, the 5'UTR includes an internal ribosome entry site or IRES. The 3'UTR may contain one or more regulatory sequences, such as binding sites for amino acid sequences that enhance the stability of mRNA molecules, binding sites for regulatory RNA molecules (such as miRNA molecules), and / or signal sequences involved in the intracellular trafficking of mRNA molecules.

[0149] On the basis of the aforementioned embodiment, in some embodiments, the target gene fragment further comprises one or more additional regulatory sequences, such as binding sites for amino acid sequences that enhance mRNA molecule stability, binding sites for amino acid sequences that enhance mRNA molecule translation, regulatory elements (such as riboswitches), binding sites for regulatory RNA molecules (such as miRNA molecules), and / or nucleotide sequences that have a positive impact on translation initiation. In addition, within the 5'UTR, preferably there is no functional upstream open reading frame, out-of-frame upstream translation initiation site, out-of-frame upstream start codon, and / or a nucleotide sequence that produces a secondary structure that reduces or prevents translation. The presence of such nucleotide sequences in the 5'UTR can have a negative impact on translation.

[0150] The coding sequence of the protein, polypeptide, or fragment thereof comprises codons that can be translated into an amino acid sequence. The coding sequence may comprise all naturally occurring codons encoding amino acids, or may comprise some or all artificially synthesized codons. In some embodiments, some or all of the codons are codon-optimized. In some embodiments, some or all of the codons encode unnatural amino acids.

[0151] In some embodiments, the DNA molecule further comprises structural elements on the 5' end of the target gene segment that are necessary to initiate or regulate transcription of the RNA, and these structural elements are known in the art. In some embodiments, the structural elements comprise at least a promoter. Promoters and their sequences are known in the art and include weak promoters, medium-strength promoters, strong promoters, mini promoters, or core promoters. In certain specific embodiments, the promoter is a strong promoter. In some embodiments, the promoter can initiate transcription of the target gene segment and / or poly(A) tail in prokaryotes. In some embodiments, the promoter can initiate transcription of the target gene segment and / or poly(A) tail in eukaryotes. The "promoter" comprises at least one transcription recognition site followed by a transcription factor binding site. The recognition and binding sites can interact with amino acid sequences that mediate or regulate transcription. The binding site is closer to the target gene segment than the recognition site. The binding site can be, for example, a Pribnow box in prokaryotes or a TATA box in eukaryotes. For example, in some embodiments, when using the Pribnow box, the transcription recognition site can be located at about 35bp upstream of the transcription start site, and the transcription factor binding site can be located at about 10bp upstream of the transcription start site. In some embodiments, the promoter comprises at least one other regulatory element, such as an upstream element rich in AT at about 40 and / or 60 nucleotides before the transcription start site, and / or an additional regulatory element that enhances promoter activity between the recognition site and the binding site. In some embodiments, the promoter is a strong promoter, that is, the promoter comprises a sequence that promotes transcription of the aforementioned RNA coding sequence. Strong promoters are well known to those skilled in the art, such as OXB18, OXB19 and OXB20 promoters derived from the RecA promoter of Escherichia coli, or can be identified or synthesized by conventional laboratory procedures. In some embodiments, the promoter is a T7 promoter. In some embodiments, the promoter also comprises additional regulatory elements before it, such as an enhancer that can promote transcription of the aforementioned RNA coding sequence in a DNA plasmid.

[0152] The present application also provides a library comprising the aforementioned engineered DNA molecules. In some embodiments, the library comprises at least two DNA molecules having different Poly(A) tail encoding sequences.

[0153] In addition, the present application also provides the use of the above-mentioned engineered DNA molecules in stably amplifying a poly (A) tail coding sequence or a coding sequence of an RNA with a poly (A) tail. In some embodiments, the method for amplifying a poly (A) tail coding sequence or a coding sequence of an RNA with a poly (A) tail is as shown below in the method for stably amplifying a poly (A) tail transcription template DNA in vitro.

[0154] Engineered RNA and libraries

[0155] The present application provides an RNA comprising the aforementioned poly(A) tail and a target gene fragment on the 5' side of the poly(A) tail encoding sequence. In some embodiments, the RNA further comprises a 5'-cap structure. In some embodiments, the RNA is mRNA.

[0156] As used herein, "mRNA" (messenger RNA) is any RNA, naturally occurring, non-naturally occurring, or modified, that encodes at least one protein, polypeptide, or fragment thereof, and the mRNA has the ability to be translated to produce the encoded protein, polypeptide, or fragment thereof in vitro, in vivo, in situ, or ex vivo. Therefore, the mRNA can be a mature mRNA or a pre-mature mRNA, and the elements or structures that it must contain or selectively contain are known in the art. In some embodiments, the mRNA contains coding sequences for a plurality of necessary functional components to express, regulate, or enhance the expression level of the protein, polypeptide, or fragment thereof. The functional components include, but are not limited to, a 5' cap, a 5'UTR, a 3'UTR, and the like. Both 5'UTR and 3'UTR are typically transcribed from genomic DNA and are elements that pre-mature mRNA possesses. As a mature mRNA,

[0157] The term "5' cap" is located at the 5' end of the mRNA and contains a methylated guanylate, which is linked to the 5' end of the mRNA via pyrophosphate, forming a 5',5'-triphosphate linkage with its adjacent nucleotide. There are generally three types of 5' cap structures (m7G5'ppp5'Np, m7G5'ppp5'NmpNp, and m7G5'ppp5'NmpNmpNp), referred to as type O, type I, and type II, respectively. Type O refers to unmethylated ribose of the terminal nucleotide, type I refers to methylation of the ribose of one terminal nucleotide, and type II refers to methylation of the ribose of both terminal nucleotides. In some embodiments, the 5' cap can be simultaneously added to the polynucleotide during the in vitro transcription reaction to produce a 5'-guanosine cap structure using the following chemical RNA cap analogs: 3'-O-Me-m7G(5')ppp(5')G [ARCA cap], G(5')ppp(5')A, G(5')ppp(5')G, m7G(5')ppp(5')A, m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA), or m7G(5')ppp(5')(2'-OMeA)pG (CleanCapAG) according to the manufacturer's protocol. For example, in some embodiments, 5' capping of the modified RNA can be completed post-transcriptionally using a vaccinia virus capping enzyme to produce an O-type cap structure: m7G(5')ppp(5')G (New England BioLabs, Ipswich, MA). Type I cap structures can be generated using both vaccinia virus capping enzyme and 2'-O methyl-transferase to produce m7G(5')ppp(5')(2'-OMeA)pG. Type II cap structures can be generated from type I cap structures by 2'-O-methylation of the 5'-third from the last nucleotide using 2'-O methyl-transferase. Type III cap structures can be generated from type II cap structures by 2'-O-methylation of the 5'-fourth from the last nucleotide using 2'-O methyl-transferase.

[0158] In some embodiments, some or all of the uridine in the mRNA is chemically modified uridine.

[0159] In some embodiments, some or all of the uridine in the mRNA is pseudouridine or 1-methyl-pseudouridine.

[0160] In some embodiments, some or all of the uridine nucleotides in the mRNA are substituted with pseudouridine (ψ) nucleotides or N1-methylpseudouridine (m1ψ) nucleotides.

[0161] In some embodiments, the mRNA further comprises a stabilizing element. Stabilizing elements may include, for example, a histone stem-loop. In some embodiments, the mRNA comprises a coding region, at least one histone stem-loop, and optionally, a poly(A) sequence or polyadenylation signal. The poly(A) sequence or polyadenylation signal should generally enhance the expression level of the encoded protein. In some embodiments, the mRNA comprises a combination of a poly(A) sequence or polyadenylation signal and at least one histone stem-loop. Although the two have alternative mechanisms in nature, their synergistic effect can increase protein expression to levels exceeding that observed with either element alone. The synergistic effect of the combination of poly(A) and at least one histone stem-loop is independent of the order of the elements or the length of the poly(A) sequence. In some embodiments, the histone stem-loop is typically derived from a histone gene and comprises two adjacent partially or completely reverse-complementary sequences separated by a spacer (composed of a short sequence) that form a loop through intramolecular base pairing. Unpaired loop regions are generally unable to base pair with either of the stem-loop elements. The stability of the stem-loop structure generally depends on the length, the number of mismatches or bulges, and the base composition of the paired region. In some embodiments, wobble base pairing (non-Watson-Crick base pairing) can occur. In some embodiments, the at least one histone stem-loop sequence comprises 15 to 45 nucleotides in length.

[0162] In some embodiments, one or more AU-rich sequences of the mRNA can be removed. These sequences are sometimes referred to as AURES, which are destabilizing sequences found in the 3' UTR. AURES can be removed from the mRNA. Alternatively, AURES can be retained in the mRNA.

[0163] In some embodiments, the mRNA is configured in a lipid nanoparticle (LNP). In some embodiments, lipids are mixed with the mRNA to form lipid nanoparticles. In some embodiments, RNA is formulated in lipid nanoparticles. In some embodiments, the lipid nanoparticles are first formed into empty lipid nanoparticles and are combined or wrapped with the mRNA of the vaccine just before administration (e.g., within a few minutes to an hour).

[0164] The lipid nanoparticles generally comprise ionizable lipids, non-cationic lipids, sterols and PEG lipid components and target nucleic acids, such as the above-mentioned mRNA. Lipid nanoparticles of the present disclosure can be produced using components, compositions and methods as generally known in the art, see, for example, PCT / US2016 / 052352, PCT / US2016 / 068300, PCT / US2017 / 037551, PCT / US2015 / 027400, PCT / US2016 / 047406, PCT / US2016000129, PCT / US2016 / 014280, PCT / US2017 / 037551, PCT / US2017 / 037552, PCT / US2017 / 037551, PCT / US2017 / 0 S2016 / 014280, PCT / US2017 / 038426, PCT / US2014 / 027077, PCT / US2014 / 055394, PCT / US2016 / 52117, PCT / US2012 / 069610, PCT / US2017 / 027492, PCT / US2016 / 059575, and PCT / US2016 / 069491, all of which are incorporated herein by reference in their entirety.

[0165] The present application also provides a library comprising the aforementioned mRNA molecules, wherein the library comprises at least two mRNA molecules having different Poly(A) tails.

[0166] The present application also provides the use of the mRNA and the mRNA library. Using at least two or more mRNA molecules with poly (A) tails having different influence gradients on the expression of mRNA, it can be used to regulate the expression of the coding sequence of the aforementioned protein, polypeptide or fragment thereof. For example, by adjusting the ratio of different mRNA molecules in a library having the two or more mRNA molecules, or by introducing one or more of the two or more mRNA molecules with the same or different contents at different times.

[0167] cell

[0168] The application also provides cells comprising the aforementioned engineered DNA molecules, which can be stored and / or amplified in the cells. In some embodiments, the cells are prokaryotic cells, and the DNA molecules can be replicated in the prokaryotic cells. In some embodiments, the cells are prokaryotic cells, and the DNA molecules can be replicated and / or transcribed in the prokaryotic cells. In some embodiments, the DNA molecules are eukaryotic cells, and the DNA molecules can be replicated in the cells. In some embodiments, the DNA molecules can be transcribed and / or replicated in the DNA cells.

[0169] In some embodiments, the cell is a prokaryotic cell. In some embodiments, the cell is a bacterium, an actinomycete, a cyanobacterium, a mycoplasma, a rickettsia, and a chlamydia. In some embodiments, the cell is selected from the group consisting of: Bacillus subtilis, Lactobacillus, Acetobacter, Corynebacterium, Brevibacterium, Arthrobacter, Pseudomonas, and Micrococcus. In some embodiments, the cell is a recA ‐ In some embodiments, the cell is Escherichia coli. In some embodiments, the cell is Escherichia coli, and the Escherichia coli is selected from: K-12 and its derivatives, and B strain and its derivatives. In some embodiments, the Escherichia coli is selected from: MG1655, DH5 or DH5α, DH10B, BL21, DB3.1, HB101, JM109, JM110, MC1061, MG1655, Pir1, Stbl2, Stbl3, Top10, XL1Blue, XL10Gold, BLR, HMS174, Tuner, Rostetta2, Lemo21, T7Express, Origami2, etc. In some embodiments, the cell is selected from Streptomyces, Micromonospora, and Nocardia. In some embodiments, the cell is a fungus. In some embodiments, the cell is selected from yeast or mold.

[0170] method

[0171] The present application provides a method for stably amplifying a poly(A) tail transcription template DNA in vitro to reduce the mutation frequency of the poly(A) tail transcription template sequence when the DNA is replicated in large quantities in cells. The method comprises: amplifying the cells containing the engineered DNA molecule.

[0172] In some embodiments, prior to amplifying the cells, the step of introducing the engineered DNA molecule into the cells may include chemical or electroporation. In some embodiments, the introduction may be a natural endocytosis of the engineered DNA molecule by the cells.

[0173] In some embodiments, after amplifying the cells, the method further comprises extracting cellular DNA and synthesizing the RNA by in vitro transcription. In some embodiments, after amplifying the cells, the method further comprises inducing transcription of the RNA in the cells, and then extracting and isolating the RNA therein. In some embodiments, the method further comprises extracting cellular DNA and transducing it into a second cell that can transcribe the RNA. In some embodiments, the transduction comprises administering to a human being, the administration being selected from the group consisting of: intravenous, intraperitoneal, subcutaneous, intracranial, intrathecal, intraarterial (e.g., via the carotid artery), intramuscular, and intratumoral injection or perfusion.

[0174] In addition, the present application also provides a method for regulating protein expression, including:

[0175] Introducing two or more of the aforementioned engineered DNA molecules into target cells at different times and / or in different quantitative ratios; or

[0176] Two or more of the aforementioned RNA molecules are introduced into target cells at different times and / or in different quantitative ratios.

[0177] Wherein, the two or more aforementioned engineered DNA molecules and the two or more aforementioned RNA molecules have different Poly (A) tails, and the Poly (A) tails have different influence gradients on the expression amount of RNA.

[0178] In some embodiments, the present application also provides a method for regulating protein expression, comprising introducing the aforementioned engineered DNA molecule or the aforementioned RNA molecule into a target cell. In some embodiments, the coding sequence of the poly(A) tail encoded by the DNA and the poly(A) tail contained in the RNA comprises a structure selected from the following:

[0179] Element a-element c-element b-element c-element b-element c-element b-element c-element b;

[0180] Element b-element c-element b-element c-element a-element d-element b-element c-element b-element c-element b;

[0181] Element b-element c-element b-element c-element b-element d-element a-element c;

[0182] element a-element d-element b-element c-element b-element c-element b; or

[0183] Element b-element c-element b-element c-element b-element d-element a.

[0184] In some embodiments, the coding sequence of the poly(A) tail encoded by the DNA and the poly(A) tail contained in the RNA comprises a structure selected from the group consisting of:

[0185] 60A-G-19A-G-19A-G-19A-G-3A;

[0186] 7A-C-18A-G-60A-element d-7A-C-18A-G-14A;

[0187] 60A-element d-19A-G-19A-G-17A;

[0188] 19A-G-19A-G-19A-element d-60A;

[0189] 19A-G-19A-G-19A-element d-60A-G;

[0190] 19A-G-19A-G-19A-element d-60A;

[0191] 19A-C-19A-C-19A-element d-60A; and

[0192] 19A-T-19A-T-19A-element d-60A.

[0193] In some embodiments, the coding sequence of the Poly(A) tail encoded by the DNA and the Poly(A) tail contained in the RNA comprises the structure: 60A-element d-19A-G-19A-G-17A or 19A-G-19A-G-19A-element d-60A.

[0194] The two elements connected by "-" are directly connected, and there is no nucleotide between the two elements.

[0195] In the above-mentioned Poly(A) tail structure, "yA" represents the number of consecutive A's in element a or element b, where y is a natural number. For example, 19A means that it contains 19 consecutive A's; 60A means that it contains 60 consecutive A's.

[0196] In some embodiments, the coding sequence of the Poly(A) tail encoded by the DNA and the Poly(A) tail contained in the RNA comprises a polynucleotide sequence selected from the following, or consists of any one polynucleotide sequence selected from the following: SEQ ID NOs: 1-10.

[0197] It should be understood that the present application includes various aspects, embodiments and combinations of the aspects and / or embodiments described herein. The above description and subsequent examples are intended to illustrate rather than limit the scope of the present application. Other aspects, improvements and modifications within the scope of the present application will be apparent to those skilled in the art. Therefore, those of ordinary skill in the art will recognize that the scope of the present application also includes the improvements and modifications to the aspects and embodiments. Example

[0198] Example 1: Construction of Poly(A) tail

[0199] Conventional genetic engineering methods were used to construct the Poly(A) tail and the DNA sequence encoding the Poly(A) tail shown in Table 1 below.

[0200] Table 1.

[0201] Example 2: Testing Poly(A) Function Using Luciferase Coding Sequence as an Example

[0202] 2.1 Testing the replication stability of mRNA-encoding DNA molecules in prokaryotic cells

[0203] Using luciferase as the protein coding region, the stability of different poly(A) variants in E. coli and their effects on luciferase expression in cells were investigated.

[0204] 1) Construction of a universal vector containing the luciferase protein coding region

[0205] The universal vector uses the Escherichia coli cloning vector pUC57 as the vector backbone, and the T7 promoter sequence (5'-TAATACGACTCACTATAAGG-3'), 5'UTR, luciferase protein, 3'UTR and polyadenylic acid string poly (dA:dT) are arranged in sequence between the Xba I restriction site and the EcoR I restriction site of its multiple cloning site.

[0206] 2) The polyadenylation string poly (dA: dT) in the universal vector was replaced with P1-P10 of the present application and controls C1-C4 (A60-10nt spacer-A60 (control C1), A30-10nt spacer-A70 (control C2), A60-1nt spacer-A60 (control C3) or A60-6nt spacer-A60 (control C4) C1C2 is derived from the patent literature (U.S. Patent No. US 10717982B2)).

[0207] All primers required for constructing P1-P10 and controls C1-C4 were synthesized and double digested with two restriction endonucleases to excise the poly(dA:dT) from the universal vector constructed in 1). Then, P1-P10 and C1-C4 were ligated to the poly(dA:dT)-excised vector using T4 DNA ligase 1, completing the replacement of the poly(dA:dT) in the universal vector.

[0208] 3) Detection of the replication stability of different poly(A) variants in E. coli

[0209] After sequencing confirmation, the vector plasmid constructed in step 2) was transformed into E. coli DH5α. The transformed plates were grown at 30°C for plasmid extraction and sequencing. After sequencing, the stability and base deletions of the different poly(A) variants were analyzed and calculated based on the sequencing results. Replication stability was measured as the percentage of clones without any base changes; a higher percentage indicated greater plasmid replication stability in E. coli.

[0210] The results show (see Figure 1, Figure 2), the specific experimental results are as follows:

[0211] A total of 100 clones were tested against C1, 15 clones had base deletions, accounting for 15%; the number of correct clones was 85, accounting for 85%.

[0212] A total of 50 clones were tested against C2, and all clones were correct without any base changes or deletions, with a correct clone percentage of 100%.

[0213] A total of 50 clones were tested against C3, 9 clones had base deletions, accounting for 18%; the number of correct clones was 41, accounting for 82%.

[0214] A total of 50 clones were tested using control C4, 14 of which had base deletions, accounting for 28%; 36 clones were correct, accounting for 72%.

[0215] A total of 100 clones were tested in P1, 9 clones had base deletions, accounting for 9%; the number of correct clones was 91, accounting for 91%.

[0216] A total of 100 clones were tested in P2, 12 of which had base deletions, accounting for 12%; the number of correct clones was 88, accounting for 88%.

[0217] A total of 62 clones were tested in P3, 5 of which had base deletions, accounting for 8%; the number of correct clones was 57, accounting for 92%.

[0218] P4 tested a total of 50 clones, of which 3 clones had base deletions, accounting for 6%; the number of correct clones was 47, accounting for 94%.

[0219] A total of 50 clones were tested in P5, of which 4 clones had base deletions, accounting for 8%; the number of correct clones was 46, accounting for 92%.

[0220] A total of 50 clones were tested in P6, and 5 clones had base deletions, accounting for 10%; the number of correct clones was 45, accounting for 90%.

[0221] A total of 50 clones were tested in P7, 7 clones had base deletions, accounting for 14%, and 43 clones were correct, accounting for 86%.

[0222] A total of 50 clones were tested in P8, 3 clones had base deletions, accounting for 6%, and 47 clones were correct, accounting for 94%.

[0223] A total of 50 clones were tested in P9, 4 of which had base deletions, accounting for 8%, and 46 were correct clones, accounting for 92%.

[0224] A total of 50 clones were tested in P10, 5 clones had base deletions, accounting for 10%, and the number of correct clones was 45, accounting for 90%.

[0225] Based on the results of the correct clone ratio and the number of deleted bases, the poly(A) variants designed in this application are superior to or comparable to the existing technologies in terms of replication stability in E. coli cells. Among them, the replication stability of poly(A) variants P3, P4, and P8 is the highest, and the replication stability of P3, P4, and P8 is comparable to that of C2, with no statistically significant difference (p>0.05, χ 2 The replication stability of P3, P4, and P8 was better than that of the control C1, C3, and C4, and the difference was statistically significant (p < 0.05, χ 2 test).

[0226] Example 3 Testing the poly(A) function using the HPV antigen protein coding sequence as an example

[0227] 1) Construction of plasmids with HPV as protein coding region

[0228] As described above, vectors containing luciferase-encoding genes in combination with different poly(A) sequences were constructed in Example 1. Based on these vectors, the luciferase-encoding gene was replaced with an HPV-encoding gene using conventional molecular cloning methods. The main elements were arranged in the order of the T7 promoter sequence (5'-TAATACGACTCACTATAAGG-3'), 5'UTR, HPV antigen protein encoding sequence, 3'UTR, and poly(A) encoding sequence.

[0229] 2) Small-scale bacterial culture to test the stability of four HPV poly(A) variants in Escherichia coli

[0230] After sequencing confirmed the HPV vector plasmids containing P1, P2, P3, and P4 constructed in step 1), they were transformed into E. coli DH5α and grown on plates at 30°C for plasmid extraction and sequencing. After sequencing, the stability and base deletions of the different poly(A) variants were analyzed and calculated based on the sequencing results. Stability was measured as the percentage of clones without any base changes; a higher percentage indicated greater stability.

[0231] The results showed (Figure 3, Figure 4) that when the target gene was replaced with the HPV antigen coding sequence,

[0232] A total of 88 clones were tested against C1, 47 clones had base deletions, accounting for 53%, and 41 clones were correct, accounting for 47%.

[0233] A total of 50 clones were tested against C2, of which 1 clone had a base deletion, accounting for 2%, and 49 clones were correct, accounting for 98%.

[0234] A total of 101 clones were tested in P1, 14 of which had base deletions, accounting for 14%; the number of correct clones was 87, accounting for 86%.

[0235] A total of 100 clones were tested in P2, 12 clones had base deletions, accounting for 12%, and 88 clones were correct, accounting for 88%.

[0236] A total of 70 clones were tested in P3, 4 clones had base deletions, accounting for 6%, and 66 clones were correct, accounting for 94%.

[0237] P4 tested a total of 50 clones, 9 of which had multiple base deletions, accounting for 18%; the number of correct clones was 41, accounting for 82%.

[0238] Considering the mutation rate and the average number of base deletions, when the protein-coding gene was replaced by the luciferase in Example 1 with the HPV antigen protein, the different poly(A) variants of the present application still maintained high replication stability; among them, the stability of P3 and C2 was comparable, with no statistically significant difference (p>0.05, χ 2 Compared with the other novel variants in this application, the clone stability was the best. Furthermore, the probability of large deletions in C2 was 1 / 50 (2%), while the probability of large deletions in P3 was 1 / 70 (1.4%). Because large poly(A) deletions can affect the in vivo expression and efficacy of mRNA products, P3 better meets product requirements. These results demonstrate the universal applicability of the poly(A) variants designed in this application across various protein coding regions.

[0239] As described above, in Examples 1 and 2, the plates transformed with E. coli were cultured overnight in a 30°C biochemical incubator, and the resulting clones were sequenced to assess replication stability. In addition, since the culture temperature of E. coli affects the rate of DNA replication, it also affects replication stability. For Example 3, the present application also compared the sequencing tests performed on the plates transformed with E. coli after culture in a 37°C biochemical incubator. The results showed (Figure 5) that culture at 37°C greatly increased the base deletion ratio of the control C1, from 53% when cultured at 30°C to 98%. Unlike the control, there was no significant difference in the mutation rates of P1, P2, and P3 under the two temperature conditions, indicating that the poly (A) variants designed in the present application still have high replication stability in the examples for different temperature culture conditions of E. coli, and their application is universal.

[0240] 3) Detection of the stability of three poly(A) variants in large-scale fermentation and at different generations

[0241] The production of mRNA drugs must rely on large-scale fermentation to prepare a sufficient amount of template plasmids, and the stability of the plasmids during fermentation (in this application, the stability of the plasmids specifically refers to the stability of poly dA: dT) is crucial for producing mRNA drugs with uniform quality. On the other hand, in order to meet the stability requirements of different batches of production, it is necessary to establish a strain library containing the target plasmid, including strain libraries of different generations such as a primary library and a secondary library, so it is necessary to evaluate the plasmid stability in Escherichia coli of different generations. In response to the above two problems, the present application detected the stability of P1 and P3 between different generations of the fermentation process in Example 3. According to the sequencing results, each poly (A) variant selected 4 correct Escherichia coli clones and cultured them separately through fermentation. The results showed that in the 3rd, 5th, 7th, and 9th generations of seed passage, the plasmids of the 4 clones of P1 and P3 remained stable without any base changes.

[0242] Example 4 Luciferase mRNA expression level test in mice

[0243] In eukaryotic cells, a certain length of poly (A) tail is crucial for protecting the 3' end of mRNA, maintaining mRNA stability and promoting protein expression. Under the influence of physiological or environmental factors in the body, poly (A) gradually becomes shorter, thereby triggering mRNA degradation. This application investigates the effects of different poly (A) variants on protein expression levels. We used in vivo expression assays in mice to evaluate the effects of different poly A variants on luciferase activity. During the implementation of this application, luciferase mRNA-LNP containing control C2, as well as P3, P4, P5, P8, and P9 were injected intramuscularly into mice. Six hours after the injection, the animals were imaged and the fluorescence intensity was quantitatively compared to determine the effects of different poly (A) on the in vivo activity of luciferase. The specific experimental process is as follows:

[0244] Luciferase mRNA was synthesized by in vitro transcription. Linearized DNA was digested with the type II restriction endonuclease BspQ I. The 3'-end of the linearized DNA contained various poly(A) residues: control C2, P3, P4, P5, P8, or P9. The linearized DNA served as a template for in vitro transcription. A 100 μl reaction system contained 1X reaction buffer, 5 mM each of ATP, CTP, N1M-UTP, and GTP (final concentration), 4 mM CleanCap AG (final concentration), and 5 μl of in vitro transcriptase. The reaction mixture was thoroughly mixed and incubated at 37°C for 3 h. The in vitro transcribed mRNA was collected by LiCl precipitation and finally dissolved in enzyme-free water.

[0245] Animal experiments: In vitro synthesized luciferase mRNA was encapsulated into LNPs. The resulting mRNA stock solution was dispersed in 20 mM acetic acid (pH 5.0) to obtain an mRNA solution with a concentration of 200 μg / mL. A lipid mixture was prepared by mixing the mRNA and lipid mixture at a molar ratio of ionizable lipid: cholesterol: DSPC: DMG-PEG2000 = 50:38.5:10:1.5. The mRNA and lipid mixture were mixed by controlling the flow rates of the aqueous and oil phases using a T-type mixing system. The syringe pump was activated to allow the mRNA solution and lipid mixture to mix to form LNPs. The solution was then diluted 10-fold with diluent, concentrated by centrifugation through an ultrafiltration tube, and then exchanged three times. The resulting solution was adjusted to pH 7.0-8.0 by adding Tris aqueous solution to obtain an LNP-encapsulated mRNA solution. LNPs are lipid nanoparticles. The concentration and particle size of the LNP-encapsulated mRNA were determined using a Ribogreen RNA quantification kit (Invitrogen, R11490) and a Darwin ZetaSizer particle size analyzer. The molar ratio of the four-component LNPs was SM102:DSPC:cholesterol:DMG-PEG2000 = 50:10:38.5:1.5. After encapsulation, the LNPs were quality-controlled by measuring particle size, encapsulation efficiency, and PDI. These results demonstrated that the prepared LNPs met the standards for a particle size range of 50nm-150nm, a PDI <0.3, and an encapsulation efficiency >90%, making them suitable for subsequent experiments. The mRNA content in the LNPs was determined using the ribogreen assay, and the LNPs were then diluted to an mRNA content of 100ng / μL.

[0246] BALB / c mice were randomly divided according to body weight and acclimated for 2-3 days before dosing. Five mice were injected intramuscularly with 100 μl (10 μg mRNA) per mouse for the control group (C2) and P3, P4, P5, P8, and P9. Five mice were injected intramuscularly with PBS for the control group. Six hours after injection, the animals were imaged and fluorescence values ​​were calculated. The results (Figures 7-8) showed that compared with the control group (C2), the expression activity of P3 was significantly increased by 1.8-fold, a statistically significant difference (p < 0.01, student's t-test). Expression levels of P4, P5, P8, and P9 were comparable to those of C2, with no significant differences (p > 0.05, student's t-test).

[0247] The sequences used in the above examples of the present application are shown in the following sequence listing. It should be understood that the following sequences are merely exemplary sequences of the embodiments of the present application and are not intended to limit the present application. The nucleic acid sequences in the following sequence listing may represent DNA sequences or RNA sequences. When representing RNA sequences, "T" represents uridine.

[0248] Sequence Listing:

Claims

1. An engineered DNA molecule that can replicate in a cell, comprising a polyadenosine tail (Poly A tail) coding sequence, wherein the Poly (A) tail coding sequence comprises a unique element a and at least one element b, and at least one element c and / or at least one element d: The element a is composed of a plurality of consecutive adenine (A) nucleotides, and the length of the element a is ≥20 nt; The element b is composed of a plurality of consecutive A nucleotides, and the length of the element b is in the range of 3nt≤b<20nt; The element c consists of a non-A nucleotide, and the nucleotide is selected from T, C, and G nucleotides; The element d is composed of any two or more consecutive nucleotides, and the nucleotides are selected from A, T, C, and G nucleotides, wherein the nucleotides at the 5' and 3' ends of the element d are not A nucleotides, and it does not contain more than 3 consecutive A nucleotides; the length of the element d ranges from 2nt≤d≤20nt; wherein element a and element b are not adjacent, element c and element d are not adjacent, And the Poly(A) tail coding sequence does not contain elements b adjacent to each other, does not contain elements c adjacent to each other, and does not contain elements d adjacent to each other.

2. The DNA molecule according to claim 1, wherein the length of the Poly(A) tail coding sequence is 101 to 200 nt or 101-150 nt or 120 to 150 nt or 130-140 nt or 120-135 nt or 123-125 nt. 3 . The DNA molecule according to claim 1 , wherein the 3′ end of the poly(A) tail encoding sequence is an A nucleotide or a non-A nucleotide. The DNA molecule according to any one of claims 1 to 3 , wherein the element a is ≤ 80 nt.

5. The DNA molecule according to any one of claims 1 to 3, wherein the element a is 30 to 70 nt, 35 to 65 nt, 40 to 60 nt, or 45 to 55 nt, preferably 60 nt.

6. The DNA molecule according to any one of claims 1 to 5, wherein 50% or more of the polynucleotides of the element a are located in the 5' portion or 3' portion of the poly(A) tail encoding sequence.

7. The DNA molecule according to any one of claims 1 to 6, wherein the element b is 3 nt to 10 nt, 10 to 19 nt, 12 to 15 nt, 14 to 17 nt or 16 to 19 nt, preferably 19 nt.

8. The DNA molecule according to any one of claims 1 to 7, wherein the number of the element b is 2 to 10, preferably 2 to 5, and more preferably 3.

9. The DNA molecule according to any one of claims 1 to 8, wherein the element c is G.

10. The DNA molecule according to any one of claims 1-9, wherein the number of the elements c is 2 to 10, 3 to 8, or 4 to 6 or 2-5, preferably 2.

11. The DNA molecule according to any one of claims 1 to 10, wherein the element d comprises a palindromic sequence.

12. A DNA molecule according to any one of claims 1-11, wherein the element d is 3 to 18 nt, 5 to 16 nt, 4 to 10 nt, or 6 to 12 nt, preferably 6 nt.

13. A DNA molecule according to any one of claims 1 to 12, wherein the element d is selected from any one or more of the following sequences: GATATC (SEQ ID NO: 15), GTATAC (SEQ ID NO: 16), GAATCT (SEQ ID NO: 17), GCATATGACT (SEQ ID NO: 18) and GATATCGTATAC (SEQ ID NO: 19).

14. The DNA molecule according to any one of claims 1 to 13, wherein the element d is selected from any one or more of the following nucleotide sequences: SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO:

17.

15. The DNA molecule according to any one of claims 1 to 14, wherein the nucleotide sequence of the element d is as shown in SEQ ID NO:

15. 16 . The DNA molecule according to claim 1 , wherein the number of the element d is 0-5, preferably 1-3, and more preferably 1.

17. The DNA molecule according to any one of claims 1-16, wherein when element c and element d exist at the same time, the total number of element c and element d is 2-15, preferably 3-5, and more preferably 3.

18. The DNA molecule according to any one of claims 1 to 17, wherein the 3' portion of the Poly(A) tail encoding sequence, preferably the 1 / 2 portion of the Poly(A) tail encoding sequence close to the 3' end, comprises one or more non-A nucleotides.

19. The DNA molecule according to any one of claims 1-18, wherein the structure of the Poly (A) tail coding sequence is: Element a-element c-element b-element c-element b-element c-element b-element c-element b; Element b-element c-element b-element c-element a-element d-element b-element c-element b-element c-element b; Element b-element c-element b-element c-element b-element d-element a-element c; element a-element d-element b-element c-element b-element c-element b; or Element b-element c-element b-element c-element b-element d-element a.

20. The DNA molecule according to any one of claims 1-19, wherein the structure of the Poly(A) tail coding sequence is: Element a-element d-element b-element c-element b-element c-element b; the element a is 60 nt in length, the element b is 16 to 19 nt in length, and the element d is 6 nt in length.

21. The DNA molecule according to any one of claims 1-20, wherein the structure of the Poly(A) tail coding sequence is: Element b-element c-element b-element c-element b-element d-element a; element a is 60 nt in length, element b is 16 to 19 nt in length, and element d is 6 nt in length.

22. The DNA molecule according to any one of claims 1 to 21, wherein the poly (A) tail encoding sequence is shown in any one of SEQ ID NOs: 1 to 10.

23. The DNA molecule according to any one of claims 1 to 22, wherein the poly (A) tail encoding sequence is shown as SEQ ID NO: 3 or SEQ ID NO:

4.

24. The DNA molecule according to any one of claims 1-23, further connected to a target gene fragment at the 5' end of the Poly(A) tail coding sequence, wherein the target gene fragment and the Poly(A) tail coding sequence together encode RNA.

25. The DNA molecule according to any one of claims 1-24, further comprising a replicon.

26. The DNA molecule according to any one of claims 1-25, further comprising a resistance gene.

27. The DNA molecule according to any one of claims 1-26, further comprising a promoter that initiates transcription of the RNA.

28. The DNA molecule according to any one of claims 1-27, wherein the target gene fragment comprises a 5'UTR coding sequence.

29. The DNA molecule according to any one of claims 1-28, wherein the target gene fragment comprises a protein coding sequence or a non-protein coding sequence.

30. The DNA molecule according to any one of claims 1-29, wherein the target gene fragment comprises a 3'UTR coding sequence.

31. The DNA molecule of any one of claims 1-30 comprises a replicon, an antibiotic resistance gene, a promoter, a 5'UTR coding sequence, a protein coding sequence, and a 3'UTR coding sequence.

32. The DNA molecule according to any one of claims 1-31, wherein the protein coding sequence encodes an HPV (human papillomavirus) protein, preferably the HPV protein is derived from HPV type 16 and / or type 18.

33. The DNA molecule according to any one of claims 1-32, wherein the protein coding sequence encodes HPV E2, E6 or E7 protein, a fusion protein of E6 and E7 protein polypeptide fragments, or a fusion protein of E2, E6 and E7 protein polypeptide fragments, preferably the HPV protein is derived from HPV type 16 and / or type 18.

34. The DNA molecule according to any one of claims 1-33, wherein the protein coding sequence encodes the polypeptide shown in SEQ NO:

26.

35. A DNA molecule according to any one of claims 1-34, comprising a polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25, or a synonymous mutant of the polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25, or a polynucleotide sequence having more than 85% sequence identity with the polynucleotide sequence as shown in any one of SEQ ID NOs: 22-25 or a synonymous mutant thereof.

36. The DNA molecule according to any one of claims 1-35, which is a DNA plasmid.

37. A cell comprising a DNA molecule according to any one of claims 1-36.

38. The cell according to claim 37 is a prokaryotic cell.

39. The cell according to claim 37 is Escherichia coli.

40. An RNA molecule encoded by a DNA molecule according to any one of claims 1-36.

41. The RNA molecule according to claim 40, wherein the RNA further comprises a 5'-cap structure and / or part or all of the uridine in the RNA is chemically modified uridine; preferably, part or all of the uridine in the RNA is pseudouridine or 1-methyl-pseudouridine.

42. A DNA coding sequence for a Poly(A) tail according to any one of claims 1-36.

43. A Poly(A) tail sequence encoded by the DNA coding sequence of the Poly(A) tail according to any one of claims 1-36.

44. Use of a DNA coding sequence of a poly(A) tail according to claim 42 for making the replication of a DNA molecule encoding an RNA more conservative in a host cell, wherein the poly(A) tail is located at the 3' end of the RNA.

45. The use according to claim 44, wherein the host cell is a prokaryotic cell, preferably Escherichia coli.

46. ​​Use of the Poly(A) tail sequence according to claim 43 for regulating the expression of an RNA molecule in a host cell, wherein the Poly(A) tail is located at the 3' end of the RNA.

47. The use according to claim 46, wherein the host cell is a eukaryotic cell, preferably a mammalian cell, and more preferably a human cell.

48. A library comprising the DNA molecules according to any one of claims 1-36.

49. A library comprising RNA molecules encoded by a DNA molecule according to any one of claims 1-36.

50. A method for regulating protein expression, comprising: Introducing a plurality of DNAs in the DNA library according to claim 48 into target cells at different times and / or in different quantitative ratios; or The multiple RNAs in the RNA library of claim 49 are introduced into target cells at different times and / or in different quantitative ratios.

51. A hybrid molecule of DNA and RNA, which carries the same genetic information as the DNA molecule according to any one of claims 1-36, the same genetic information as the Poly(A) tail according to claim 42, or the same genetic information as the RNA molecule according to claim 40.